Dr Agarwals Eye Hospital financials

Key numbersby financial year

₹ crore except per share
Tap a line for its trendCurrentlast closeFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
2,437————
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
95.795.725.232.927.4
81.881.896.451.343.8
2,424————
471471397319268
—+18.6%+24.4%+19.2%—
14514511991.174.7
30.9%30.9%29.8%28.5%27.9%
99.799.779.164.554.5
70.170.154.746.436.9
14.9%14.9%13.8%14.5%13.8%
₹147.02₹147.02₹114.62₹97.23₹77.43
—+28.3%+17.9%+25.6%—
——94.589.869.6
——94.589.869.6
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

DRAGARWQ₹5,112.00

Dr Agarwals Eye Hospital Limited

· Pharma & Health
₹ CrorePeersKMCSHILKOVAILOTUSEYEGPTHEALTHGKSLSHALBYINDRAMEDCOARTEMISMEDMcap ₹2,437 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current
last close
Market Capitalization————2,437.4
- Cash, Equiv & ST Investments27.432.925.295.795.7
+ Total Debt43.851.396.481.881.8
Enterprise Value————2,423.6
Revenue267.9319.3397.2470.9470.9
Growth %, YoY—+19.2+24.4+18.6—
EBITDA74.791.1118.5145.3145.3
Margin %27.8828.5229.8430.8630.86
EBIT54.564.579.199.799.7
Net Income36.946.454.770.170.1
Margin %13.7814.5213.7614.8914.89
EPS, Adj (current shares)77.4397.23114.62147.02147.02
Growth %, YoY—+25.6+17.9+28.3—
Cash from Operations69.689.894.5——
Free Cash Flow69.689.894.5——
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.

Dr Agarwals Eye Hospital financials and key ratios

Figures from the company's filings with NSE

In FY26 its consolidated net profit was ₹70.1 crore on revenue of ₹471 crore. Its debt-to-equity ratio was 0.24 on 31 March 2026.

Latest balance sheet
31 March 2026

Dr Agarwals Eye Hospital at a glance · consolidated

ROE (FY26)
25.2%−4.6 pts vs FY25ROCE 16.9%
Debt to equity
0.24net cash ₹14 Cr
Net worth
₹346 Cr31 March 2026
EPS (FY26)
₹147.02

Questions

Is Dr Agarwals Eye Hospital debt free?

No. Dr Agarwals Eye Hospital had borrowings of ₹81.8 crore on 31 March 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.24. Its cash and current investments were ₹95.8 crore, so it held net cash of ₹14 crore.

What is the Dr Agarwals Eye Hospital debt to equity ratio?

Dr Agarwals Eye Hospital's debt-to-equity ratio was 0.24 on 31 March 2026: borrowings of ₹81.8 crore against total equity of ₹346 crore.

What is the Dr Agarwals Eye Hospital net worth?

Dr Agarwals Eye Hospital's net worth — shareholders' equity in its consolidated balance sheet — was ₹346 crore on 31 March 2026.

What is the Dr Agarwals Eye Hospital ROE and ROCE?

In FY26, Dr Agarwals Eye Hospital's return on equity (ROE) was 25.2% and its return on capital employed (ROCE) was 16.9%. ROE is net profit divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was 29.8% and ROCE 16.8%.

What is the Dr Agarwals Eye Hospital revenue and profit in FY26?

In FY26 (April 2025–March 2026), Dr Agarwals Eye Hospital's consolidated net profit was ₹70.1 crore, up 28.3% from ₹54.7 crore in FY25, on revenue from operations of ₹471 crore (up 18.6%). Over three years, from FY23, net profit was up 89.9%.

Dr Agarwals Eye Hospital vs Lotus Eye Hospital and Institute: how do they compare?

In FY26, Dr Agarwals Eye Hospital earned net profit of ₹70.1 crore on revenue of ₹471 crore, against ₹8 lakh on ₹53.7 crore for Lotus Eye Hospital and Institute. Dr Agarwals Eye Hospital's operating margin was 21.2% (Lotus Eye Hospital and Institute −0.7%) and its return on equity 25.2% (Lotus Eye Hospital and Institute 0.1%).

What is the Dr Agarwals Eye Hospital book value per share?

Dr Agarwals Eye Hospital's book value per share was ₹726.29 on 31 March 2026: shareholders' equity of ₹346 crore divided by the 47.68 lakh shares in issue.

What is the Dr Agarwals Eye Hospital EPS?

Dr Agarwals Eye Hospital's basic earnings per share (EPS) were ₹147.02 in FY26, against ₹116.28 in FY25.

What is the Dr Agarwals Eye Hospital dividend in 2026 and its record date?

In 2026, Dr Agarwals Eye Hospital has declared one dividend: ₹4 with record date 2 September 2026.

How does Dr Agarwals Eye Hospital compare with its peers?

On FY26 consolidated figures, against Lotus Eye Hospital and Institute: Dr Agarwals Eye Hospital's operating margin of 21.2% is the higher of the two (Lotus Eye Hospital and Institute −0.7%; peer average −0.7%); its return on equity of 25.2% is the higher of the two (Lotus Eye Hospital and Institute 0.1%; peer average 0.1%); its revenue growth over three years of 20.7% a year is the higher of the two (Lotus Eye Hospital and Institute 4.5% a year; peer average 4.5% a year).

Where do these Dr Agarwals Eye Hospital figures come from?

From Dr Agarwals Eye Hospital's own consolidated results, balance sheets and shareholding patterns filed with NSE, and NSE prices (the latest used here: the 29 October 2026 close). Ratios are calculated by Alphave from those filings as each answer describes.

Consolidated figures from the company's filings with NSE; prices are NSE closing prices.